CARDIAC BIOMARKERS MARKET ANALYSIS

Cardiac Biomarkers Market Size and Trends

The global cardiac biomarkers market is estimated to be valued at USD 15.10 Bn in 2024 and is expected to reach USD 36.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.3% from 2024 to 2031.

To learn more about this report, Request sample copy

The increasing prevalence of cardiovascular diseases and the growing demand for point-of-care testing are the major factors contributing to the market growth. The market is witnessing various trends such as increased adoption of high sensitivity troponin tests and launch of novel cardiac biomarkers by key players. Moreover, rising investments by public and private players to develop innovative biomarkers with high sensitivity and specificity for accurate detection of acute myocardial infarction and other heart conditions are expected to offer lucrative opportunities for the market players over the forecast period.

Rising Burden of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases is one of the major drivers of growth in the cardiac biomarkers market. Cardiovascular diseases have become one of the leading causes of mortality globally. According to the World Health Organization, cardiovascular diseases account for over 17 million deaths each year, which is estimated to grow to over 23.6 million by 2030. The key factors responsible for the rising cardiovascular disease burden include rapidly aging populations, increasing adoption of sedentary lifestyles and unhealthy diets, rising stress levels, smoking, and a growing prevalence of conditions like obesity and diabetes. With cardiovascular diseases posing such a huge threat to public health and economies, focus on early detection, diagnosis, and management of these conditions has increased substantially. Cardiac biomarkers have emerged as vital tools supporting clinicians in making critical treatment decisions, such as confirming or ruling out occurrences of heart attacks. The widespread application of cardiac biomarkers in clinical practice for evaluating patients with signs and symptoms of acute coronary syndrome is boosting the market growth. For instance, according to data from the British Heart Foundation released in January 2022, the most prevalent heart conditions globally in 2021 included coronary heart disease (affecting 200 million), peripheral arterial disease (110 million), stroke (100 million), and atrial fibrillation (60 million). Regional variations were noted, with North America reporting 46 million cases, Europe 99 million, Africa 58 million, South America 32 million, and Asia/Australia 310 million. This widespread prevalence is expected to increase the demand for early detection and treatment, potentially broadening the market's scope over the forecast period.

To learn more about this report, Request sample copy

Rising Focus on Innovation and Development of Novel Biomarkers

The growing focus of leading industry players and research institutions on innovation and development of novel cardiac biomarkers is another major factor fueling the growth of this market. Currently available biomarker tests only facilitate the detection of myocardial necrosis and injury. However, clinicians also require biomarkers that can provide accurate information on other aspects such as myocardial stress, ischemia, remodeling, and other pre-damage states. Therefore, newer biomarkers are being pursued that can enable the detection of cardiac abnormalities at early pre-damage stages as well. Considerable investments are being made for identifying novel biomarkers through omics-based techniques like proteomics and metabolomics. Some of the promising novel cardiac biomarkers in clinical trials or early stages of development include soluble ST2, galectin-3, matrix metalloproteinases, placental growth factor, ischemia-modified albumin, and others. The development of panels of multiple biomarkers is also gaining attention for facilitating comprehensive cardiac risk assessment. The pipeline of innovative biomarkers in the clinical development and approval phases will continue fueling market revenue in the coming years.